REF-1776 · Tedeschi & Giorgi, 2026 · Clinical Journal of Sport Medicine · Paper · PubMed

A scoping review found only three randomised trials of gait retraining (step rate, impact reduction, foot strike) in runners with patellofemoral (front-of-knee) pain; the retrained groups' pain fell 2-4 points on a visual analogue scale with better knee-function scores and some passing calf discomfort, but the abstract reports no comparison against the control groups, so the authors' "effective" outruns what it shows

Main caveat: Three trials, each testing a different strategy, so no strategy has more than one trial behind it.
limited, mixed evidenceMeasured on recreational to trained athletesRead from the abstract only

Tedeschi and Giorgi mapped the evidence on gait retraining for patellofemoral pain syndrome in runners, looking at pain, function, biomechanics and adverse effects. Searching five databases under the Joanna Briggs Institute scoping framework, they found three randomised trials, which tested a change in step rate, a reduction in impact, and a change in foot strike.

In the retrained groups pain on a visual analogue scale improved by 2 to 4 points, Kujala and Knee Outcome Survey activities-of-daily-living scores rose, and biomechanical measures showed lower patellofemoral joint stress and impact forces. Some runners had calf discomfort while adapting, which settled.

The authors conclude that gait retraining is effective, with lasting pain relief, functional and biomechanical benefits, and that protocols should be individual and introduced gradually; they also note that long-term retention of the changes and the best training parameters are still unclear.

Participants

Runners diagnosed with patellofemoral pain syndrome in three RCTs; the number of runners, sex split, ages and running level are not in the abstract.

Protocol

Search: MEDLINE, Cochrane CENTRAL, Scopus, PEDro and Web of Science; dates not in the abstract.
Eligibility: gait retraining interventions in runners diagnosed with patellofemoral pain syndrome.
Outcomes: pain, function, biomechanical adaptations, adverse effects.
Included: 3 RCTs — step-rate (cadence) modification, impact reduction, foot-strike adjustment.
Not in the abstract: the trials' names, sizes, comparators, follow-up lengths, retraining doses, any risk-of-bias or certainty appraisal, and between-group results.

Key Results

OutcomeRetrained groups (as reported)
Pain (visual analogue scale)improved by 2 to 4 points, significant
FunctionKujala and Knee Outcome Survey ADL scores increased (no values in the abstract)
Biomechanicslower patellofemoral joint stress, lower impact forces, better load distribution
Adverse effectstransient calf discomfort in some during adaptation, resolved
Against control groupsnot reported in the abstract

Practical Application

Gait retraining is a possible add-on for a runner with diagnosed front-of-knee pain, not a proven stand-alone treatment. In three trials the retrained runners' pain fell by 2-4 points on a visual analogue scale (its range is not in the abstract), but the abstract does not say how the control groups did, so the share due to retraining is not shown.
This is not treatment advice; a physiotherapist or physician diagnoses the knee pain and decides whether gait retraining belongs in the plan.
Some runners had passing calf discomfort while adapting — the one adverse effect reported; introducing changes gradually is the authors' advice, not a tested comparison.
Read beside [SYNTH-94] and [SYNTH-55]: the guides put a clinician's knee exercise and education first and treat step-rate change as an option, because in the base's runner trial gait retraining showed no evidence of added benefit over education alone (REF-917). The abstract does not name its three trials, so whether that trial is among them is not known; nothing in this review overturns the guides.
Overlaps with [REF-1775]: the umbrella review's included reviews cover the same kinds of trials (step rate, soft landing, foot strike in runners with patellofemoral pain), so these three trials may well sit inside it, but neither source names its trials and the overlap cannot be checked (our reading); do not count the two reviews as independent support.

Limitations

Three trials, each testing a different strategy, so no strategy has more than one trial behind it.
The abstract reports within-group change in the retrained groups; between-group differences and the comparators are not given.
No risk-of-bias or certainty appraisal is reported; a scoping design maps rather than weighs the evidence.
The conclusion of "sustained" relief sits beside the authors' own statement that long-term retention is unclear; follow-up lengths are not in the abstract.
Written from the abstract only: the trials' identities and sizes, search dates, doses, follow-up, registration and funding are unknown.
How this entry was checked and changed
Why this level

a scoping review with a systematic search (five databases, JBI framework), so not a narrative review; risk of bias not read (abstract only) and none reported; graded down from the B+ cap because it rests on three trials and the abstract reports only changes within the retrained groups, not between-group differences